Anthropic has warned that recursive-self-improving AI could be on the horizon, but the truth is the company is more ...

Recursion (NASDAQ: RXRX) and Exscientia PLC (NASDAQ: EXAI) have announced that their shareholders have overwhelmingly approved the proposed combination between the two companies. The transaction is ...

Anthropic's internal data shows Claude writing most of its code, an early signal of recursive self-improvement in AI.

Every organism you have ever seen, every ecosystem you have ever walked through, is the ongoing output of an algorithm that ...

In The Lancet in 1971, Julian Tudor Hart gave medicine one of its most important insights: the availability of medical care ...

Abstract: Quaternion-based machine learning algorithms have emerged as a promising candidate for four dimensional (4D) signal processing, which utilize 4D signal dimensions’ correlations for ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

Recursion Pharmaceuticals uses AI to develop drugs. The company's goal is to improve and speed up a process that is slow, expensive, and risky. Most medicines that enter the clinic never make it to ...

Recursion Pharmaceuticals uses AI to improve the process of discovering and developing drugs, making it easier and more cost-effective. Most medicines that enter clinical trials never reach the market ...

The human faculty to generate an infinite set of structured expressions in language, present in most cultures and normal ontogeny, is the most substantial evidence of the human capacity for recursion.